Skip to main content
Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
258.39
-3.09 (-1.18%)
Dec 5, 2025, 4:00 PM EST - Market closed

Labcorp Holdings Revenue by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
10.74B 10.52B 10.30B 10.15B 9.91B 9.70B 9.51B 9.41B
Diagnostics Growth
8.43% 8.53% 8.26% 7.82% 5.91% 5.22% 4.19% 2.27%
Drug Development
3.07B 3.01B 2.93B 2.92B 2.85B 2.83B 2.82B 3.51B
Drug Development Growth
7.78% 6.32% 3.87% -16.80% -32.26% -42.15% -50.00% -38.45%

Operating Income by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Diagnostics
1.72B 1.66B 1.62B 1.61B 1.60B 1.60B 1.57B 1.59B
Diagnostics Growth
7.48% 3.61% 3.08% 0.95% -1.48% -4.68% -12.13% -21.44%
Drug Development
493.20M 481.90M 466.00M 459.00M 437.20M 425.30M 422.50M 446.50M
Drug Development Growth
12.81% 13.31% 10.30% 2.80% -19.93% -34.34% -44.14% -44.26%
General Corporate Expenses
-276.30M -274.20M -268.70M -268.30M -269.00M -273.20M -382.10M -389.00M

Operating Expense Breakdown
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017
Selling, General, and Administrative
2.27B 2.29B 2.27B 2.23B 2.17B 2.12B 2.07B 2.12B
Selling, General, and Administrative Growth
4.85% 7.74% 9.41% 5.30% 2.18% 0.89% -0.65% 6.07%
Impairments
339.80M - - 349.30M - - 349.30M 349.00M 285.50M 276.50M 274.90M 296.20M - - - - - - - - - - - - - - - - - -
Impairments Growth
19.02% - - 26.33% - - 27.06% 17.83% -38.38% -40.67% - - - - - - - - - - - - - - - - - - - -
Amortization
277.80M 272.00M 265.90M 256.40M 245.20M 237.20M 226.50M 235.70M
Amortization Growth
13.30% 14.67% 17.40% 8.78% 3.42% -3.81% -13.38% -9.10%
Restructuring and Other
27.80M 39.90M 47.40M 46.00M 52.90M 42.40M 46.60M 50.20M -
Restructuring and Other Growth
-47.45% -5.90% 1.72% -8.37% 21.33% -17.19% -41.60% -40.10% -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.